Convergence Mapping
When multiple ingredients hit the same gene, the platform quantifies the convergence pattern and scores the significance instead of issuing generic flags.
Pharmacogenomic Intelligence
Every ingredient.
Every gene.
One score.
Multi-ingredient pharmacogenomic analysis at a depth and scale that did not exist until now.
Composite Signal Layer
116+
Pharmacogenes analyzed
∞
Ingredient combinations
1
Composite risk score
PGx
Pathway-aware formulation intelligence
Map every ingredient to every gene, then compress the signal into a usable decision layer.
01 — The Blind Spot
Formulations are complex. Most PGx tools still treat them like they are not.
Current pharmacogenomic tools usually analyze single drugs against single genes. But real-world formulations — compounded medications, nutraceutical stacks, and multi-ingredient therapies — create convergence patterns across many pathways at once. That includes CYP metabolism, serotonergic signaling, methylation, mitochondrial function, and more. Traditional tools do not map that complexity. Formulomics does.
02 — Built Different
Designed for the complexity others ignore.
A cleaner structure, stronger hierarchy, and mobile-first spacing make the core message easier to scan on smaller screens without losing the premium feel.
Pathway Intelligence
Ingredient-by-ingredient analysis across CYP metabolism, serotonergic signaling, methylation, mitochondrial function, and other relevant pathways.
Decision Architecture
Genotype-aware logic designed to move from population-level evidence to patient-specific formulation scenarios.
Clinical-Grade Sources
Annotations grounded in PharmGKB, CPIC, DGIdb, and peer-reviewed pharmacogenomic literature rather than marketing shorthand.
PharmGKB
CPIC
DGIdb
Peer-Reviewed Literature
03 — Early Access
The future of formulation intelligence is coming.
Request early access to Formulomics. The layout below stacks cleanly on mobile, keeps the field and button thumb-friendly, and removes the cramped desktop-first form behavior from the original page.
◆ You’re on the list. We’ll be in touch.